Skip to main content
Fig. 4 | Skeletal Muscle

Fig. 4

From: Limb-girdle muscular dystrophy type 2B causes HDL-C abnormalities in patients and statin-resistant muscle wasting in dysferlin-deficient mice

Fig. 4

Simvastatin mitigates HFD-induced weight gain and plasma lipoprotein accretion in Dysf-null mice but fails to prevent ambulatory dysfunction. A Monthly body weight measures (2, 4, 6, 8, and 11 months) in Chow and HFD-fed, vehicle, and simvastatin (SIM)-treated WT and Dysf mice. Two-way ANOVA with Tukey’s post hoc tests were used for direct mean comparisons; #P < 0.05 and compares WT SIM and Dysf SIM at the age group selected. **P < 0.01 and ***P < 0.001 independently compare both WT SIM to Dysf SIM and Dysf vehicle to Dysf SIM across the age groups selected. B End-point (11 m) step length images from Chow and HFD-fed Dysf mice treated with either vehicle or simvastatin and their quantification for all groups. Two-way ANOVA with Sidak’s post hoc tests were used for direct mean comparisons between; ••P < 0.01 and within; no significance detected. C–E End-point total plasma cholesterol (CHOL), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C) and triglycerides (TG) from Chow and HFD-fed, WT and Dysf-null mice treated with either vehicle or simvastatin. Two-way ANOVA with Sidak’s post hoc tests were used for direct mean comparisons between, •••P < 0.001 and ••••P < 0.0001, and within, *P < 0.05 and ****P < 0.0001. Mean ± SEM. A–BN = 6–9. C–FN = 8–13

Back to article page